mibavademab tirzepatide Triple Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports GLP-1-based therapies for diabetes, obesity
Description
In early 2026, CVS Caremark made headlines by removing Zepbound from some formularies, affecting Aetna members
These criteria are narrower than the general obesity indication that many commercial plans previously covered
Lavielle, M
Study Rationale SURMOUNT-1 Trial Historically, the treatment of obesity focused almost exclusively on lifestyle-based approaches
Mountjaro is used to treat Type 2 diabetes and Zepbound is used for weight loss
Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney disease
